Remission from depression : a review of venlafaxine clinical and economic evidence (Q36165233)

12 August 2017

1 reference

title

Remission from depression : a review of venlafaxine clinical and economic evidence (English)

1 reference

12 August 2017

Donald Han

1

1 reference

12 August 2017

Edward C Y Wang

series ordinal

2

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

23

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

567-581

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200523060-00004

12 August 2017

exact match

0 references

cites work

Recovery from depression, work productivity, and health care costs among primary care patients

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

12 December 2020

The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression.

1 reference

12 December 2020

Clinical guidelines for the treatment of depressive disorders

1 reference

12 December 2020

Antidepressant options: venlafaxine in perspective

1 reference

12 December 2020

Extended-release venlafaxine in relapse prevention for patients with major depressive disorder

1 reference

12 December 2020

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

12 December 2020

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

Multiple recurrences of major depressive disorder.

1 reference

12 December 2020

Prediction of relapse in recurrent affective disorder

1 reference

12 December 2020

The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys.

1 reference

12 December 2020

New standard of depression treatment: remission and full recovery

1 reference

12 December 2020

Achieving gains beyond response.

1 reference

12 December 2020

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

12 December 2020

Predictors of relapse in major depressive disorder

1 reference

12 December 2020

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

1 reference

12 December 2020

Health care costs associated with depressive and anxiety disorders in primary care.

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management

1 reference

12 December 2020

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

12 December 2020

Venlafaxine versus placebo in the preventive treatment of recurrent major depression

1 reference

12 December 2020

Cost of lost productive work time among US workers with depression.

1 reference

12 December 2020

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder

1 reference

12 December 2020

The economic burden of depression in the United States: how did it change between 1990 and 2000?

1 reference

12 December 2020

A hundred cases of suicide: clinical aspects.

1 reference

12 December 2020

Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.

1 reference

12 December 2020

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment

1 reference

12 December 2020

SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability

1 reference

12 December 2020

Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety.

1 reference

12 December 2020

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

1 reference

12 December 2020

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

1 reference

12 December 2020

Health care costs of primary care patients with recognized depression.

1 reference

12 December 2020

Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials

1 reference

12 December 2020

Excess mortality in bipolar and unipolar disorder in Sweden

1 reference

12 December 2020

Meta-analytical studies on new antidepressants.

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Pharmacotherapy to sustain the fully remitted state.

1 reference

12 December 2020

Cost of treatment failure for major depression: direct costs of continued treatment

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

Long-term treatment of depression

1 reference

12 December 2020

Labour productivity effects of prescribed medicines for chronically ill workers

1 reference

12 December 2020

Depression in the workplace: effects on short-term disability

1 reference

12 December 2020

Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS

1 reference

12 December 2020

Pharmacological prevention of suicidal behaviour

1 reference

12 December 2020

Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

Synaptic effects of antidepressants

1 reference

12 December 2020

The clinical, psychosocial, and pharmacoeconomic ramifications of remission.

1 reference

12 December 2020

The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH.

1 reference

12 December 2020

The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?

1 reference

12 December 2020

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

1 reference

12 December 2020

Treatment of major depression: is improvement enough?

1 reference

12 December 2020

Differences between prescription and consumption of antidepressants and anxiolytics.

1 reference

12 December 2020

Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population.

1 reference

12 December 2020

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

1 reference

12 December 2020

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

1 reference

12 December 2020

Residual symptoms after partial remission: an important outcome in depression

1 reference

12 December 2020

Impact of improved depression treatment in primary care on daily functioning and disability

1 reference

12 December 2020

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

12 December 2020

Depressive symptoms as a predictor of 6-month outcomes and services utilization in elderly medical inpatients.

1 reference

12 December 2020

Association of comorbidity with depressive symptoms in community-dwelling older persons.

1 reference

12 December 2020

Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study.

1 reference

12 December 2020

Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond

1 reference

12 December 2020

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

1 reference

12 December 2020

Is depression under-recognised and undertreated?

1 reference

12 December 2020

Depressed mood in a cohort of elderly medical inpatients: prevalence, clinical correlates and recognition rate.

1 reference

12 December 2020

The economic burden of depression in 1990.

1 reference

12 December 2020

10.2165/00019053-200523060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1013657988

0 references

1 reference